BridgeMD
Clinical impact of pharmacokinetic monitoring of antibiotics in critically ill patients
EU CTIS ID: 2023-504480-17-00
What this study is testing
To assess the clinical impact of pharmacokinetic monitoring of antibiotics in the critically ill patient. The following antibiotics are considered in this study: meropenem, cefepime, piperacillin/tazobactam, linezolid and daptomycin.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients who are candidates for study entry must meet the following criteria (detailed in sections 5.1 Study Type and Design): - Age ≥ 18 years. - Patients admitted to the Intensive Care Unit (ICU) who start treatment with the antibiotics under study and who meet the criteria for inclusion in the intervention or control group (detailed in sections 5.1 Study design). - Intervention group: initiation of treatment during the 48 hours prior to the plasma concentration determination (day and time set weekly). - Control group: start of treatment from the weekly time at which the plasma concentration of the intervention group is determined, until the same number of patients as the intervention group is reached that same week.
You likely can't join if
- Patients with a duration of antibiotic treatment < 72 hours, have an ICU stay < 48 hours or do not meet the inclusion criteria are excluded.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.